The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Increase In Market Value Is Predicted For The Tuberculosis Therapeutics Market During The 2026–2030 Period?
The tuberculosis therapeutics market size has experienced strong growth in recent years. It is anticipated to increase from $2 billion in 2025 to $2.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The expansion observed in the historic period can be attributed to the global tuberculosis disease burden, the widespread application of first-line TB drugs, the increase in government TB control initiatives, the availability of generic TB medications, and international financial support for TB programs.
The tuberculosis therapeutics market size is anticipated to expand significantly in the upcoming years. It is projected to achieve a value of $2.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is propelled by the increasing prevalence of multidrug-resistant TB, advancements in novel TB drug development, augmented global health funding, the broader application of digital adherence technologies, and a heightened emphasis on preventive TB treatment. Prominent trends for the forecast period involve the rising development of drug-resistant TB therapies, greater adoption of combination treatment regimens, an increased focus on shorter treatment durations, the expansion of public health TB programs, and enhanced patient adherence monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp
What Key Growth Drivers Are Influencing The Tuberculosis Therapeutics Market?
The tuberculosis therapeutics market is expected to grow due to rising co-infection rates of tuberculosis (TB) and human immunodeficiency virus (HIV). TB-HIV co-infection rates indicate the prevalence of individuals concurrently infected with both TB and HIV, a situation that complicates diagnosis, treatment, and patient outcomes because of immune suppression and overlapping epidemics. The increase in these co-infections stimulates demand for combined therapeutic approaches targeting TB infection within HIV-positive populations, leading to improved overall outcomes and a reduced burden of both diseases. For instance, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Therefore, the growth of the tuberculosis therapeutics market is driven by rising TB-HIV co-infection rates.
What Segment Categories Are Evaluated In The Tuberculosis Therapeutics Market Study?
The tuberculosis therapeutics market covered in this report is segmented –
1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)
2) By Drug Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol
3) By Route of Administration: Oral, Parenteral, Other route of administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies
What Trends Are Affecting The Growth Of The Tuberculosis Therapeutics Market?
Leading companies in the trypsin-EDTA solution market for cell dissociation are developing innovative products, including animal-based ECM dissociation solutions, to gain a competitive advantage. Animal-based ECM dissociation solutions are enzymatic or chemical formulas originating from animal sources, utilized to break down extracellular matrix components and facilitate cell detachment from tissue or culture surfaces. An example of this is TheWell Bioscience, a US-based biomedical technology company, which launched the VitroGel Organoid Recovery Solution in February 2023. The VitroGel Organoid Recovery Solution represents a significant breakthrough by enabling swift and efficient recovery of organoids from both animal-based extracellular matrix (ECM) and synthetic VitroGel hydrogels. It accomplishes complete dissociation of animal-based ECM in merely 2 minutes, with the full cell harvesting process completed in only 15 minutes, showcasing a substantial improvement over the primary existing solution that requires more than 60 minutes. Engineered for high-quality, intact organoid recovery, this solution provides superior yields, cell viability, and quality for procedures such as passaging, cryopreservation, or biochemical analysis. Furthermore, it operates at room temperature, eliminating the need for heat or cooling apparatus and facilitating comprehensive lab automation for high-throughput organoid production.
Which Companies Are Influencing The Tuberculosis Therapeutics Market?
Major companies operating in the tuberculosis therapeutics market are Pfizer Inc, Johnson & Johnson, Roche Holding AG, Merck & Co. Inc, Sanofi S.A, Novartis AG, GlaxoSmithKline plc, Viatris Inc, Cipla Limited, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Sequella Inc, AstraZeneca plc, Eli Lilly and Company, Biofabri S L, LegoChem Biosciences, BioVersys AG, SENTAN Pharma Inc, ViChem Pharmaceuticals Inc, PDS Biotechnology Corporation, BioNTech SE, Qurient Co Ltd
Access The Complete Tuberculosis Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report
Which Region Is The Primary Market For The Tuberculosis Therapeutics Market?
North America was the largest region in the tuberculosis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Tuberculosis Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=20983&type=smp
Browse Through More Reports Similar to the Global Tuberculosis Therapeutics Market 2026, By The Business Research Company
Hepatitis Therapeutics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Anti Infective Drugs Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report
Therapeutic Bcg Vaccines Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model